IDIX – Caris & Co. started coverage yesterday with a Buy rating and a $17 target: <a href="http://www.gainerstoday.com/UserRecommendations.aspx?StockID=&UserID=2965&SortField=StockID&SortDirection=ASC&Year=0&PageNumber=3" target="_blank">http://www.gainerstoday.com/UserRecommendations.aspx?StockID=&UserID=2965&SortField=StockID&SortDirection=ASC&Year=0&PageNumber=3</a> Analyst ratings are BS, of course; still, it’s nice to know that someone besides me thinks the IDX899 deal with GSK is a good one.